CL2020003220A1 - Nueva proteína con propiedades antiinflamatorias - Google Patents

Nueva proteína con propiedades antiinflamatorias

Info

Publication number
CL2020003220A1
CL2020003220A1 CL2020003220A CL2020003220A CL2020003220A1 CL 2020003220 A1 CL2020003220 A1 CL 2020003220A1 CL 2020003220 A CL2020003220 A CL 2020003220A CL 2020003220 A CL2020003220 A CL 2020003220A CL 2020003220 A1 CL2020003220 A1 CL 2020003220A1
Authority
CL
Chile
Prior art keywords
inflammatory properties
new protein
seq
prevention
isolated
Prior art date
Application number
CL2020003220A
Other languages
English (en)
Inventor
Valerie Mary Corrigall
Gabriel Stavros Panayi
Original Assignee
Immune regulation ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1809703.0A external-priority patent/GB201809703D0/en
Priority claimed from US16/007,742 external-priority patent/US10858409B2/en
Application filed by Immune regulation ltd filed Critical Immune regulation ltd
Publication of CL2020003220A1 publication Critical patent/CL2020003220A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona una proteína aislada o recombinante que consiste en la secuencia de aminoácidos de acuerdo con la SEQ ID NO: 3 o SEQ ID: NO: 4 y su uso en la prevención o el tratamiento de una afección inflamatoria.
CL2020003220A 2018-06-13 2020-12-11 Nueva proteína con propiedades antiinflamatorias CL2020003220A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1809703.0A GB201809703D0 (en) 2018-06-13 2018-06-13 Novel protein with anti-inflammatory properties
US16/007,742 US10858409B2 (en) 2018-06-13 2018-06-13 Protein with anti-inflammatory properties

Publications (1)

Publication Number Publication Date
CL2020003220A1 true CL2020003220A1 (es) 2021-10-01

Family

ID=66999851

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003220A CL2020003220A1 (es) 2018-06-13 2020-12-11 Nueva proteína con propiedades antiinflamatorias

Country Status (14)

Country Link
EP (1) EP3807303A1 (es)
JP (1) JP7570324B2 (es)
KR (1) KR20210039339A (es)
CN (2) CN119285737A (es)
AU (2) AU2019285831B2 (es)
BR (1) BR112020025398A2 (es)
CA (1) CA3103370A1 (es)
CL (1) CL2020003220A1 (es)
CO (1) CO2020016749A2 (es)
IL (1) IL279350A (es)
MX (1) MX2020013569A (es)
SG (1) SG11202012363XA (es)
WO (1) WO2019239126A1 (es)
ZA (1) ZA202100115B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3255084A1 (en) * 2022-03-31 2023-10-05 Revolo Biotherapeutics Limited COMPOSITIONS AND THEIR USE IN PROCESSES FOR TREATING INTESTINAL INFLAMMATION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9822115D0 (en) * 1998-10-09 1998-12-02 King S College London Treatment of inflammatory disease
GB0106161D0 (en) 2001-03-13 2001-05-02 King S College London Immunomodulators
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
WO2006073446A2 (en) * 2004-04-28 2006-07-13 The Trustees Of The University Of Pennsylvania Peptide-mediated protein transduction into cells the hematopoietic lineage
ES2525096T3 (es) * 2005-04-19 2014-12-17 Kings College London Uso de bip contra la pérdida ósea y osteoporosis
LT2872644T (lt) * 2012-07-12 2017-10-10 Uab Baltymas Natyvių rekombinantinių sekretuojamų žmogaus endoplazminio tinklo šaperonų gamyba, panaudojant jų natyvias signalines sekas, mielių raiškos sistemose
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
KR101731908B1 (ko) * 2015-08-18 2017-05-11 서울대학교산학협력단 p62 ZZ 도메인에 결합하는 리간드 또는 아르기닌화된 BiP에 의해 매개되는 오토파지 활성을 통한 신경변성 질환 예방 및 치료

Also Published As

Publication number Publication date
AU2019285831B2 (en) 2023-11-16
ZA202100115B (en) 2022-07-27
MX2020013569A (es) 2021-05-27
SG11202012363XA (en) 2021-01-28
CA3103370A1 (en) 2019-12-19
WO2019239126A1 (en) 2019-12-19
JP2021528100A (ja) 2021-10-21
EP3807303A1 (en) 2021-04-21
AU2024200977B2 (en) 2026-02-12
JP7570324B2 (ja) 2024-10-23
CO2020016749A2 (es) 2021-04-08
BR112020025398A2 (pt) 2021-04-06
AU2024200977A1 (en) 2024-03-07
CN112888704A (zh) 2021-06-01
IL279350A (en) 2021-01-31
KR20210039339A (ko) 2021-04-09
CN112888704B (zh) 2024-08-02
CN119285737A (zh) 2025-01-10
AU2019285831A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
EP4442816A3 (en) Mutated glycoprotein of vesicular stomatitis virus
CY1121658T1 (el) Πεπτιδια και χρηση αυτων
ECSP18002929A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
PE20220505A1 (es) Moleculas de union a tigit y pd-1/tigit
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
EA201990298A1 (ru) Способы и композиции для лечения рака
CO2021017664A2 (es) Péptidos
CO2017013404A2 (es) Variantes de il-37
PE20151978A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
MX2017006748A (es) Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades.
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
WO2019094938A3 (en) Methods and compositions for the treatment of wounds
MX2020010030A (es) Metodos y composiciones que comprenden proteina d tensoactiva (sp-d).
AR102890A1 (es) Polipéptidos que comprenden una secuencia de aminoácidos g3p de bacteriófago sin señal de glucosilación
CL2020003220A1 (es) Nueva proteína con propiedades antiinflamatorias
MX2020004218A (es) Métodos y composiciones para inhibir las actividades biológicas de adam10.
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами
MX380750B (es) Composición farmacéutica para tratar y/o prevenir el cáncer.
MX2024001541A (es) Composiciones proteicas para el tratamiento de enfermedades inflamatorias.
ES2722803T3 (es) Fármaco que contiene lectinas de muérdago recombinantes para el tratamiento del melanoma maligno
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.